AstraZeneca PLC (NASDAQ:AZN) Given Consensus Rating of “Moderate Buy” by Analysts

AstraZeneca PLC (NASDAQ:AZNGet Rating) has received an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $8,246.29.

AZN has been the topic of several research reports. TheStreet raised AstraZeneca from a “c+” rating to a “b-” rating in a report on Thursday, March 10th. SVB Leerink increased their price objective on AstraZeneca from $65.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, February 24th. JPMorgan Chase & Co. increased their price objective on AstraZeneca from £100 ($122.49) to £120 ($146.99) in a research note on Thursday, April 7th. Credit Suisse Group increased their price objective on AstraZeneca from GBX 9,000 ($110.24) to £110 ($134.74) in a research note on Friday, April 8th. Finally, Kepler Capital Markets lowered AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, May 18th.

Shares of AZN stock opened at $63.55 on Thursday. The business’s fifty day moving average price is $64.96 and its 200 day moving average price is $61.80. AstraZeneca has a 1-year low of $53.63 and a 1-year high of $71.70. The company has a quick ratio of 0.66, a current ratio of 1.00 and a debt-to-equity ratio of 0.77.

AstraZeneca (NASDAQ:AZNGet Rating) last announced its quarterly earnings data on Friday, April 29th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.86 by $0.09. The firm had revenue of $11.39 billion for the quarter, compared to analyst estimates of $10.96 billion. AstraZeneca had a positive return on equity of 25.35% and a negative net margin of 2.56%. AstraZeneca’s quarterly revenue was up 55.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.81 earnings per share. As a group, equities research analysts anticipate that AstraZeneca will post 3.3 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the business. AXA S.A. purchased a new position in AstraZeneca in the third quarter valued at about $36,000. Capital World Investors lifted its position in shares of AstraZeneca by 4.3% during the 3rd quarter. Capital World Investors now owns 5,179,166 shares of the company’s stock worth $311,017,000 after purchasing an additional 214,424 shares during the last quarter. MML Investors Services LLC increased its stake in AstraZeneca by 23.8% during the third quarter. MML Investors Services LLC now owns 83,964 shares of the company’s stock valued at $5,043,000 after acquiring an additional 16,134 shares during the period. LPL Financial LLC increased its stake in AstraZeneca by 12.8% during the third quarter. LPL Financial LLC now owns 222,852 shares of the company’s stock valued at $13,384,000 after acquiring an additional 25,316 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of AstraZeneca by 9.3% in the 3rd quarter. Wellington Management Group LLP now owns 53,145,564 shares of the company’s stock valued at $3,191,923,000 after purchasing an additional 4,526,346 shares during the period. 20.46% of the stock is currently owned by hedge funds and other institutional investors.

About AstraZeneca (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Articles

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.